🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

65,67 USD

Máx. histórico

89,55

119 días

Caída desde máximo

-26,67%

Rango 52 semanas

58,80 – 90,87

Variación hoy

-4,79%

Cierre anterior

68,97

Rango de hoy

65,45 – 69,59

Volumen hoy

1.228.468

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 23 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/03/2017 9,88 10,55 9,80 10,31 +3,83% 7,59% 1.564.000
07/03/2017 10,01 10,38 9,82 9,93 -2,84% 5,59% 1.112.700
06/03/2017 10,30 10,54 9,71 10,22 +4,18% 8,06% 3.113.700
03/03/2017 10,84 10,86 9,64 9,81 -7,28% 11,30% 3.096.200
02/03/2017 11,01 12,05 10,25 10,58 -19,73% 16,35% 7.638.700
01/03/2017 13,90 14,43 12,86 13,18 -3,30% 11,32% 1.258.300
28/02/2017 13,58 13,94 13,00 13,63 +0,74% 6,92% 869.500
27/02/2017 13,25 13,68 12,97 13,53 +2,81% 5,36% 707.200
24/02/2017 12,90 13,28 12,76 13,16 +0,69% 4,02% 447.100
23/02/2017 13,36 13,49 12,81 13,07 -1,80% 5,09% 491.800
22/02/2017 13,44 13,65 12,87 13,31 -1,41% 5,80% 896.500
21/02/2017 14,27 14,44 13,40 13,50 -4,66% 7,29% 880.700
17/02/2017 13,93 14,41 13,50 14,16 +2,76% 6,53% 1.111.900
16/02/2017 12,86 14,12 12,77 13,78 +7,99% 10,50% 2.625.200
15/02/2017 12,81 13,22 12,50 12,76 -0,62% 5,62% 503.200
14/02/2017 12,57 12,96 12,50 12,84 +1,90% 3,66% 293.700
13/02/2017 12,89 12,93 12,48 12,60 -1,87% 3,46% 456.500
10/02/2017 13,80 13,80 12,70 12,84 -7,09% 7,97% 943.100
09/02/2017 13,26 14,04 13,24 13,82 +4,38% 6,03% 587.200
08/02/2017 13,33 13,47 12,91 13,24 -1,63% 4,20% 427.300
07/02/2017 13,58 13,74 13,27 13,46 -0,96% 3,46% 531.400
06/02/2017 13,50 14,00 13,46 13,59 +0,74% 4,00% 439.000
03/02/2017 13,27 13,53 12,86 13,49 +2,51% 5,04% 482.900
02/02/2017 13,05 13,36 12,52 13,16 +0,08% 6,44% 411.200
01/02/2017 13,17 13,40 12,72 13,15 +0,38% 5,16% 595.400
31/01/2017 12,10 13,25 12,00 13,10 +7,38% 10,33% 1.127.700
30/01/2017 13,14 13,14 12,09 12,20 -4,84% 7,99% 580.100
27/01/2017 13,54 13,62 12,40 12,82 -7,10% 9,01% 1.269.300
26/01/2017 13,56 14,12 13,51 13,80 +2,45% 4,50% 959.800
25/01/2017 13,47 13,67 13,33 13,47 +0,67% 2,52% 337.100